Clinical Scorecard: In Memoriam: Dr. Edward Shelton Henderson, Trailblazer in Chemotherapy
At a Glance
Category
Detail
Condition
Haematological cancers, especially leukaemias including acute lymphoblastic leukaemia (ALL)
Key Mechanisms
Development and advancement of chemotherapy protocols for leukaemias; fostering multidisciplinary research integrating clinical and basic sciences
Target Population
Patients with haematological malignancies, particularly children with ALL
Care Setting
Academic medical centers, cancer research institutes, clinical trial groups, and later regulatory and veterans’ healthcare settings
Key Highlights
Contributed to breakthroughs in therapy of acute lymphoblastic leukaemia leading to a 90% cure rate in children
Led the Leukaemia Service at the National Cancer Institute and headed Medicine A at Roswell Park Cancer Institute
Promoted multidisciplinary collaboration between clinicians and pharmacologists and participated in cooperative clinical trials (CALGB)
Guideline-Based Recommendations
Diagnosis
Utilize multidisciplinary approaches integrating clinical and laboratory research for accurate diagnosis of haematological cancers
Management
Implement chemotherapy protocols developed through cooperative clinical trials for acute lymphoblastic leukaemia
Encourage collaboration between clinical and basic scientists to optimize treatment strategies
Monitoring & Follow-up
Engage in ongoing clinical trials and data interpretation to refine therapeutic outcomes
Monitor patient response closely within cooperative group settings
Risks
Awareness of treatment-related toxicities and the need for careful clinical oversight during chemotherapy
Patient & Prescribing Data
Children and adults with haematological malignancies, especially acute lymphoblastic leukaemia
Chemotherapy regimens developed under Dr. Henderson’s leadership significantly improved cure rates, emphasizing the importance of clinical trial participation and multidisciplinary care
Clinical Best Practices
Foster collaboration between clinical hematologists, oncologists, and pharmacologists
Participate in cooperative clinical trial groups to advance treatment standards
Maintain critical evaluation of emerging data and therapies to improve patient outcomes
Provide mentorship and education to junior clinicians and researchers to sustain progress in haematological cancer treatment
